Apomorphine
- Generic Name
- Apomorphine
- Brand Names
- Apokyn
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17NO2
- CAS Number
- 58-00-4
- Unique Ingredient Identifier
- N21FAR7B4S
- Background
Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.
Apomorphine was granted FDA approval on 20 April 2004.
- Indication
Apomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.
- Associated Conditions
- Mobility decreased
Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05979415
- Locations
- 🇺🇸
Cenexel Rocky Mountain Clinical Research, Englewood, Colorado, United States
🇺🇸CenExel iResearch Atlanta (Decatur), Decatur, Georgia, United States
🇺🇸Quest Research Institute, Farmington Hills, Michigan, United States
Sublingual Apomorphine in Refractory Restless Legs Syndrome
- Conditions
- Restless Legs Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2022-09-06
- Lead Sponsor
- William Ondo, MD
- Target Recruit Count
- 16
- Registration Number
- NCT05529095
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Apomorphine in Severe Brain-injured Patients
- Conditions
- Disorder of Consciousness
- Interventions
- Other: Sodium chloride 9mg/ml
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- University of Liege
- Target Recruit Count
- 48
- Registration Number
- NCT05213169
- Locations
- 🇧🇪
University of Liege, Liege, Belgium
🇧🇪Hôpital Valdor - ISoSL, Liège, Belgium
🇪🇸VITHAS, Valencia, Spain
Motor Network Physiology
- Conditions
- Parkinson DiseaseEssential Tremor
- Interventions
- Other: Subcortical Stimulation
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT04957095
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04887467
- Locations
- 🇫🇷
CHU Pontchaillou, Rennes, France
Apomorphine Effects on Pain in Parkinson's Disease
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 40
- Registration Number
- NCT04879134
- Locations
- 🇨🇦
Movement Disorder Program, Foothills Medical Center, Alberta Health Services, Calgary, Alberta, Canada
Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)
- Conditions
- Corticobasal DegenerationProgressive Supranuclear Palsy
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Target Recruit Count
- 7
- Registration Number
- NCT04786158
- Locations
- 🇫🇷
Hôpital Fondation Adolphe de Rothschild, Paris, Ile-de-France, France
Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals
- Conditions
- Parkinson Disease
- Interventions
- Drug: Dopaminergic Agonist + Apomorphine
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT03693872
- Locations
- 🇫🇷
CH Caremeau, Nîmes, France
🇫🇷CHU La Pitié Salpêtrière, Paris, France
🇫🇷Hôpital Gui de Chauliac, Montpellier, France
Treating Severe Brain-injured Patients With Apomorphine
- Conditions
- Disorder of Consciousness
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- University of Liege
- Target Recruit Count
- 8
- Registration Number
- NCT03623828
- Locations
- 🇧🇪
University Hospital of Liège, Liège, Belgium
🇧🇪Neurological Hospital Center William Lennox, Ottignies, Brabant Wallon, Belgium
A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
- Conditions
- Motor OFF Episodes Associated With Parkinson's Disease
- Interventions
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT03391882
- Locations
- 🇮🇹
IRCCS San Raffaele Pisana-Clinical Trial Center, Rome, Italy
🇦🇹Wilhelminenspital, Department of Neurology, Vienna, Austria
🇩🇪Klinik Haag i.OB, Haag In Oberbayern, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.